Allergan Aesthetics, an AbbVie Company

What Allergan Aesthetics, an AbbVie Company does

Allergan Aesthetics is a medical aesthetics company headquartered in Irvine, California, operating as a wholly-owned subsidiary of AbbVie (NYSE: ABBV). The company develops and markets a portfolio of science-backed aesthetic products and treatments, serving both patients seeking aesthetic procedures and the healthcare providers who administer them. With approximately 2,136 employees, Allergan Aesthetics focuses on empowering confidence through aesthetic medicine, with a stated emphasis on patient care, practitioner education, and customer support across its product portfolio.

The business operates a B2B2C commercial model: aesthetic products are sold to licensed medical practitioners — including dermatologists, plastic surgeons, and aesthetic injectors — who in turn deliver treatments to patients. Revenue mechanics are not publicly disclosed in the source material, but the franchise's product portfolio and global footprint imply a combination of product sales, training services, and customer support offerings typical of branded medical aesthetics franchises. Distribution and marketing channels are not explicitly detailed, though the company's corporate website and AbbVie-wide digital infrastructure provide global reach.

Allergan Aesthetics originated from Allergan plc, which was acquired by AbbVie in 2020 in a transaction valued at approximately $63 billion. Since that acquisition, the aesthetics business has operated as a dedicated franchise within AbbVie's broader pharmaceutical portfolio, leveraging the parent's regulatory, commercial, and operational infrastructure while maintaining its own brand identity, clinical development focus, and practitioner engagement programs.

Name

Allergan Aesthetics, an AbbVie Company

Legal name

Allergan Aesthetics, an AbbVie Company

Website

https://global.allerganaesthetics.com

Company type

Private

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Allergan Aesthetics is a medical aesthetics subsidiary of AbbVie that develops and markets science-backed aesthetic products and treatments, serving healthcare providers and patients worldwide from its base in Irvine, California.

Ownership category

akta.pro rank

Product category

Medical Aesthetics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Health and Personal Care Retailers (456)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK)

Keywords

• Aesthetic medicine products
• Medical aesthetics treatments
• Cosmetic injectable products
• Aesthetic dermatology
• Medical aesthetics brands

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Core offering

Allergan Aesthetics develops and sells a portfolio of science-backed medical aesthetics products and treatments used by healthcare practitioners in aesthetic procedures. The company focuses on empowering patient confidence through clinically validated aesthetic choices, supported by practitioner education, customer service, and global insights into the future of aesthetics. It operates as the medical aesthetics arm of AbbVie, distributing its offerings to clinical customers worldwide.

Product overview

Allergan Aesthetics, an AbbVie Company, is a medical aesthetics company that offers a portfolio of aesthetic products and treatments. The company focuses on empowering confidence through science-backed choices. However, the source content does not provide specific details about individual product names, categories, or descriptions.

Differentiator

Problem solved

Functional benefit

Products and services

• Aesthetic medicine products and treatments portfolio A portfolio of science-backed medical aesthetics products and treatments administered by healthcare practitioners in aesthetic procedures. The portfolio supports patient confidence and addresses a range of aesthetic concerns, though individual product names are not enumerated in the source content.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights4 records

Emerging players

• Hugel: Hugel is a Korean aesthetics and biopharmaceutical company with botulinum toxin (Botulax/Letybo) and HA filler products that compete in international and increasingly U.S. and European markets. It is an emerging peer with growing relevance to Allergan Aesthetics' international injectable share.
• Croma-Pharma: Croma-Pharma is a European aesthetics company specializing in hyaluronic acid fillers, PRP, and biostimulator products. It serves as a focused European comparator in the dermal-filler and regenerative aesthetics categories where Allergan Aesthetics competes.
• Establishment Labs: Establishment Labs is a medical technology company focused on breast aesthetics and reconstruction. It operates in adjacent aesthetics categories that overlap with the broader procedural aesthetics market in which Allergan Aesthetics' physician customers operate.

Direct peers

• Galderma: Galderma is a leading global dermatology and medical aesthetics company with a portfolio spanning injectable aesthetics, skincare, and therapeutic dermatology. It is the most directly comparable pure-play aesthetics peer to Allergan Aesthetics, competing head-to-head in fillers, biostimulators, and physician-dispensed skincare.
• Merz Aesthetics: Merz Aesthetics is a major medical aesthetics competitor offering botulinum toxin (Xeomin), dermal fillers (Belotero, Radiesse), and skincare lines. It competes directly with Allergan Aesthetics across both injectable categories and physician-channel skincare.
• Evolus: Evolus is a focused aesthetics company built around its botulinum toxin product (Jeuveau), directly competing with Allergan's flagship neurotoxin franchise in the U.S. and select international markets. Its pure-play focus makes it a highly relevant comparable for injectable portfolio strategy.
• Revance Therapeutics: Revance develops and commercializes aesthetic and therapeutic injectables, including a long-acting botulinum toxin (Daxxify) that directly competes with Allergan Aesthetics' flagship neurotoxin. It is a relevant comparable for novel-toxin and aesthetics-pipeline dynamics.

Regional players

• Sinclair Pharma: Sinclair Pharma is a European-based aesthetics company with a portfolio of HA fillers and bio-stimulators primarily distributed across Europe and Latin America. It is a regional peer to Allergan Aesthetics in the dermal-filler and biostimulator categories outside the U.S. market.

Others

• AbbVie (parent / Botox franchise): AbbVie is the parent company of Allergan Aesthetics and itself reports the aesthetics segment. Including AbbVie as a reference peer is useful because AbbVie's segment economics, capital allocation, and strategic posture directly determine Allergan Aesthetics' trajectory.

Broad incumbents

• Ipsen: Ipsen markets Dysport, a competing botulinum toxin, and operates across both aesthetic and therapeutic indications through a diversified specialty pharma portfolio. It is a broader incumbent peer competing with Allergan Aesthetics in the aesthetics toxin category from a wider therapeutic footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/allergan-aesthetics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allergan Aesthetics, an AbbVie Company